Pediatric-style treatment for adults with acute lymphoblastic leukemia in Brazil
Tests a pediatric-style regimen in adults newly diagnosed with acute lymphoblastic leukemia.
Plain-language title generated from the registry record
Registry title: Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Key facts
- Where
- São Paulo, BrazilSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 16 to 50 with newly diagnosed acute lymphoblastic leukemia (ALL) who are Philadelphia chromosome negative and have not yet had main treatment.
- Age
- 16 to 50 years
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed ALL, Philadelphia chromosome negative, with 20% or more lymphoblasts in bone marrow or blood.
- Earlier treatment
- No earlier treatment, except hydroxyurea, corticosteroids, or intrathecal chemotherapy. No earlier intravenous chemotherapy.
- Biomarker or test result
- Negative for the Philadelphia chromosome.
Main reasons for not taking part
- Burkitt leukemia
- Earlier myeloproliferative disease
- Positive for the Philadelphia chromosome
- Positive test for HIV or HTLV
- Down syndrome
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 50 years old?
Source: NCT05959720, who can take part
Where in Brazil
- Instituto do Câncer do Estado de São PauloSão Paulo, BrazilContact: Wellington F Silva, MD PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Instituto do Cancer do Estado de São Paulo
- Trial code
- NCT05959720
- Record updated
- 3 November 2026
- Original description
In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.Read full original descriptionShow less
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study
In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.
Exclusion: Prior myeloproliferative disease; Prior treatment with intravenous chemotherapy; Positive serology for HIV or HTLV; Heart failure NYHA Class III or IV (appendix 4); Severe psychiatric disorder which prevents adequate compliance; Down syndrome; Total bilirubin>2x upper limit of normal (ULN); Transaminases>5x ULN; Creatinine>2,5 mg/dl; Burkitt leukemia; Philadelphia chromosome positivity through whichever methodology (RT-PCR, FISH, or conventional karyotype); ECOG>2 (appendix 3); Refusal to participate in the study.